ELX 02

Drug Profile

ELX 02

Alternative Names: ELX-02

Latest Information Update: 11 Jun 2017

Price : $50

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Eloxx Pharmaceuticals
  • Class Aminoglycosides; Small molecules
  • Mechanism of Action Ribosomal protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mucopolysaccharidosis I
  • Preclinical Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Rett syndrome

Most Recent Events

  • 02 Jun 2017 Eloxx Pharmaceuticals plans two phase II studies in Cystic fibrosis and Cystinosis (in patients harbouring non-sense mutations) over the course of 2017 and 2018
  • 02 Jun 2017 Eloxx Pharmaceuticals plans a phase Ib multiple ascending dose study to evaluate ELX 02 in healthy volunteers over the course of 2017 and 2018
  • 02 Jun 2017 Preclinical trials in Duchenne muscular dystrophy in Israel before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top